^
    23h
    TAK-012-1501: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=16, Terminated, Takeda | Trial completion date: May 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision (No safety concern)
    Trial completion date • Trial termination
    |
    cyclophosphamide • fludarabine IV • TAK-012
    8d
    IIT-2018-Gamma-DeltaTcell: Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (clinicaltrials.gov)
    P1, N=38, Recruiting, University of Kansas Medical Center | Trial completion date: Jan 2025 --> Jan 2028 | Trial primary completion date: Jan 2024 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • INB-100
    8d
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Fujian Medical University
    New P1 trial
    |
    IL4 (Interleukin 4)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    2ms
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial primary completion date: Oct 2026 --> Oct 2025
    Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • IPN60340
    2ms
    Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, The Second Affiliated Hospital of Fujian Medical University
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    2ms
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Acepodia Biotech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • ACE1831
    2ms
    SGNEGFRd2-001: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=290 --> 65 | Trial completion date: Jan 2030 --> Aug 2026 | Trial primary completion date: Jan 2029 --> Aug 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    3ms
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Jan 2028
    Trial completion date • First-in-human
    3ms
    ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE） (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Tongji Hospital
    New trial
    |
    cyclophosphamide • ACE1831
    3ms
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Acepodia Biotech, Inc. | Initiation date: Aug 2025 --> Jan 2026
    Trial initiation date
    |
    cyclophosphamide • ACE1831
    3ms
    Aflac-NBL-2002: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Emory University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • irinotecan • zoledronic acid • Unituxin (dinutuximab)
    3ms
    Genetic engineering and allogeneic optimization of Vδ1 γδ CAR-T cells (ADI-270) for cancer immunotherapy. (PubMed, J Immunother Cancer)
    A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to Vδ1 γδ T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores αβ T cell-derived engineering strategies applicable to γδ T cells, while also highlighting genome-editing innovations poised to advance next-generation γδ CAR-T development.
    Journal
    |
    CD70 (CD70 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)